Agios Pharmaceuticals

Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. We believe that dysregulation of normal cellular metabolism plays a crucial role in many diseases, including certain cancers and rare diseases Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. We intend to apply our deep understanding of metabolism, coupled with our ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.
Type
Public
HQ
Cambridge, US
Founded
2008
Size (employees)
208 (est)+63%
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has office in Cambridge
Cambridge, US

Agios Pharmaceuticals Metrics

Agios Pharmaceuticals Summary

Market capitalization

$2.13 B

Closing share price

$47.8
Agios Pharmaceuticals's current market capitalization is $2.13 B.

Agios Pharmaceuticals Financials

Agios Pharmaceuticals's revenue is $65.4 M in FY, 2014
FY, 2015FY, 2014FY, 2013

Revenue

$65.4 M$25.5 M

Revenue growth, %

155.8%

Operating income

$-119 M$-54.1 M$-38.9 M

Operating expense total

$178 M$119 M$64.4 M

Net Income

$-118 M$-53.5 M$-39.4 M

Operating cash flow

$57.7 M$-57.5 M$-19.7 M

Agios Pharmaceuticals Market Value History

Agios Pharmaceuticals News

Agios Pharmaceuticals Company Life

You may also be interested in